Matches in Wikidata for { <http://www.wikidata.org/entity/Q92057617> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q92057617 description "article scientifique publié en 2020" @default.
- Q92057617 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q92057617 description "scientific article published on 20 April 2020" @default.
- Q92057617 description "wetenschappelijk artikel" @default.
- Q92057617 description "наукова стаття, опублікована 20 квітня 2020" @default.
- Q92057617 name "Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States" @default.
- Q92057617 name "Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States" @default.
- Q92057617 type Item @default.
- Q92057617 label "Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States" @default.
- Q92057617 label "Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States" @default.
- Q92057617 prefLabel "Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States" @default.
- Q92057617 prefLabel "Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States" @default.
- Q92057617 P1433 Q92057617-A7703E76-1EEE-408D-8907-421E2A8D66F6 @default.
- Q92057617 P1476 Q92057617-3A92B6B9-6421-4BC0-AFA1-8CA4187F3227 @default.
- Q92057617 P2093 Q92057617-28B583E3-D7DD-4F1E-97C4-15E64BB58F00 @default.
- Q92057617 P2093 Q92057617-397F5310-4367-4F2B-A16B-7A37720A7602 @default.
- Q92057617 P2093 Q92057617-7D83A5E9-25D4-4EFA-981A-DE61C6B91951 @default.
- Q92057617 P2093 Q92057617-8EF4A2F4-D589-4501-99EC-5F567E8D7358 @default.
- Q92057617 P2093 Q92057617-AC3EF139-3376-49C3-AB58-B8D79903C1E3 @default.
- Q92057617 P2093 Q92057617-D143565C-73DB-4CDE-BD63-05ADD4743FE9 @default.
- Q92057617 P304 Q92057617-08717659-575F-43DA-A6D2-7F14B7FB72B5 @default.
- Q92057617 P31 Q92057617-C84D013D-BAE1-4A47-8CBE-FCCC7261C1F1 @default.
- Q92057617 P356 Q92057617-03FFE62B-392D-4D7E-A736-602C3F5C3ACF @default.
- Q92057617 P577 Q92057617-1D9A4B81-4927-45D4-9B14-ED75E5FC0238 @default.
- Q92057617 P698 Q92057617-3D0CD146-7C44-483C-876F-C00F37FD9BD6 @default.
- Q92057617 P921 Q92057617-3F7A5D65-8DD7-4186-B75F-3C59B6102A16 @default.
- Q92057617 P356 JMCP.2020.19319 @default.
- Q92057617 P698 32308099 @default.
- Q92057617 P1433 Q23894211 @default.
- Q92057617 P1476 "Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States" @default.
- Q92057617 P2093 "George Bungey" @default.
- Q92057617 P2093 "John Woolcott" @default.
- Q92057617 P2093 "Joseph C Cappelleri" @default.
- Q92057617 P2093 "Ming-Ann Hsu" @default.
- Q92057617 P2093 "Pamela Young" @default.
- Q92057617 P2093 "Stacey Chang-Douglass" @default.
- Q92057617 P304 "1-12" @default.
- Q92057617 P31 Q13442814 @default.
- Q92057617 P356 "10.18553/JMCP.2020.19319" @default.
- Q92057617 P577 "2020-04-20T00:00:00Z" @default.
- Q92057617 P698 "32308099" @default.
- Q92057617 P921 Q511097 @default.